Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

Treatment of HIV-1 infection in sub-Saharan Africa has many challenges. In this report, the safety and efficacy of three different regimens are assessed in HIV-1–infected persons in South Africa: tenofovir alafenamide fumarate (TAF)–emtricitabine (FTC)–dolutegravir (DTG), tenofovir disoproxil fumara...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2019-08, Vol.381 (9), p.803-815
Hauptverfasser: Venter, Willem D.F, Moorhouse, Michelle, Sokhela, Simiso, Fairlie, Lee, Mashabane, Nkuli, Masenya, Masebole, Serenata, Celicia, Akpomiemie, Godspower, Qavi, Ambar, Chandiwana, Nomathemba, Norris, Shane, Chersich, Matthew, Clayden, Polly, Abrams, Elaine, Arulappan, Natasha, Vos, Alinda, McCann, Kaitlyn, Simmons, Bryony, Hill, Andrew
Format: Artikel
Sprache:eng
Schlagworte:
Acquired immune deficiency syndrome
Age
AIDS
Antiretroviral drugs
Antiretroviral therapy
Body fat
Body weight gain
Bone density
CD4 antigen
Clinical trials
Creatinine
Developing countries
Drug resistance
Efavirenz
Emtricitabine
Gender
HIV
Human immunodeficiency virus
Integrase
LDCs
Low income groups
Medical research
Pharmaceutical industry
Prodrugs
Regulatory approval
Renal function
Ribonucleic acid
RNA
Tenofovir
Tuberculosis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Treatment of HIV-1 infection in sub-Saharan Africa has many challenges. In this report, the safety and efficacy of three different regimens are assessed in HIV-1–infected persons in South Africa: tenofovir alafenamide fumarate (TAF)–emtricitabine (FTC)–dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)–FTC–DTG, and the local standard-of-care regimen (TDF–FTC–efavirenz).
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa1902824